Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing surveillance of eribulin mesilate in inoperable or recurrent breast cancer
jRCT1080222004
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of eribulin in breast cancer, sponsored by Eisai Co., Ltd.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1080222004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222004.